Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Your ultimate guide to the 2024 North Carolina State Fair
Recommended
Help North Carolina rebuild: WRAL's Hurricane Helene recovery fund raises $900K+
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merus N.V. CS
(NQ:
MRUS
)
52.69
+0.95 (+1.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
266,027
Open
51.70
Bid (Size)
51.47 (1)
Ask (Size)
53.94 (1)
Prev. Close
51.74
Today's Range
51.60 - 52.74
52wk Range
19.80 - 61.61
Shares Outstanding
46,530,884
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
September 30, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
September 17, 2024
Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation
From
Merus N.V.
Via
GlobeNewswire
Performance
YTD
+84.10%
+84.10%
1 Month
+6.62%
+6.62%
3 Month
-4.70%
-4.70%
6 Month
+32.35%
+32.35%
1 Year
+151.86%
+151.86%
More News
Read More
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 06, 2024
From
Merus N.V.
Via
GlobeNewswire
MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024
August 01, 2024
Via
InvestorPlace
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
August 01, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
July 24, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
July 08, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
July 01, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
June 03, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
June 02, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Pricing of Upsized Public Offering of Common Shares
May 29, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 29, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
May 28, 2024
From
Merus N.V.
Via
GlobeNewswire
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 28, 2024
Via
Benzinga
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
May 28, 2024
From
Merus N.V.
Via
GlobeNewswire
Crude Oil Rises 1%; Verastem Shares Slide
May 24, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
May 24, 2024
Via
Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
May 24, 2024
Via
Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
May 24, 2024
Via
Investor's Business Daily
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
May 24, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 24, 2024
Via
InvestorPlace
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
May 23, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
May 23, 2024
From
Merus N.V.
Via
GlobeNewswire
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
May 13, 2024
From
Merus N.V.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.